Related references
Note: Only part of the references are listed.
Article
Oncology
Wei Yuan et al.
Summary: YTHDC2 is a novel oncogene in gastric cancer (GC) that enhances the translation efficiency of YAP by recognizing m(6)A-modified YAP mRNA, leading to increased viability, proliferation, and invasion of GC cells. Additionally, YAP/TEAD directly activates the transcription of YTHDC2, forming a positive regulatory loop. Targeting YTHDC2 may be a potential strategy for GC patients.
TRANSLATIONAL ONCOLOGY
(2022)
Review
Genetics & Heredity
Jocelyn Widagdo et al.
Summary: N6-methyladenosine modification is a crucial regulator of gene expression and protein translation. The fate of m6A-modified mRNAs is decoded by m6A readers, with YTHDC1 being the only reader located in the nucleus. In addition to its well-established role in the cytoplasm, recent studies have revealed the involvement of YTHDC1 in regulating noncoding and regulatory RNAs in the nucleus, possibly through the formation of nuclear condensates.
TRENDS IN GENETICS
(2022)
Article
Oncology
Qiang Wei
Summary: This study identified 89 candidate genes regulated by IGF2BP2-mediated m6A in HCC, with 10 significant genes associated with poor prognosis. The upregulation of these genes was also linked to immune cell infiltration and tumor purity, providing potential biomarkers for HCC diagnosis and insights for IGF2BP2 inhibition therapy.
JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2021)
Review
Oncology
Jinyan Wang et al.
Summary: IGF2BP2 is an RNA-binding protein that regulates cellular metabolism and cancer development by post-transcriptional regulation. It is also an independent prognostic factor for multiple cancer types.
CANCER CELL INTERNATIONAL
(2021)
Review
Immunology
Sha Wu et al.
Summary: Rheumatoid arthritis is characterized by immune cell infiltration and destruction of cartilage and bone. Studies have shown that m(6)A modification is related to the pathogenesis of RA, providing evidence for the development of new therapies. The relationship between m(6)A enzymes, immune cells, and RA is important for understanding and treating this autoimmune disease.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Nan Zhang et al.
Summary: N6-Methyladenosine (m6A) modification is a common posttranscriptional methylation modification of RNA, participating in various mRNA processes. Abnormal m6A modification is associated with tumors such as colorectal cancer and liver cancer, where proteins involved in m6A modification play roles in tumor growth, metastasis, and immunity.
JOURNAL OF ONCOLOGY
(2021)
Article
Oncology
Yuancheng Huang et al.
Summary: The study investigated the role of m(6)A-related lncRNAs in gastric adenocarcinoma and their prognostic value. Through analysis of gene expression and clinicopathological data, different patient clusters were identified based on m(6)A-related lncRNAs, and a prognostic signature was established. The prognostic signature showed significant predictive value for overall survival, clinicopathological characteristics, tumor microenvironment, and immune response in patients with gastric adenocarcinoma.
FRONTIERS IN ONCOLOGY
(2021)
Review
Cell Biology
Yang Wang et al.
Summary: Sepsis is a life-threatening organ dysfunction caused by a host's dysfunctional response to infection. The RNA modification m6A has been implicated in various biological processes, particularly in sepsis and immune disorders. This review systematically collects potential mechanisms linking m6A modification to sepsis-induced cardiovascular dysfunction.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Cell Biology
Runbi Ji et al.
Summary: RNA N6-methyladenosine (m(6)A) modification plays a crucial role in regulating cell fate, affecting the balance between pluripotency and differentiation in stem cells. Aberrant m(6)A modification is closely associated with the maintenance of cancer stem cells in various cancers, with important clinical implications for cancer diagnosis and therapy.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Cell Biology
Yimeng Wang et al.
Summary: m6A, the most prevalent RNA modification, plays a crucial role in physiological and pathological processes, particularly in the pathogenesis of immune-related diseases. It may serve as a promising epitranscriptomic target for preventing and treating autoimmune disorders.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Jie Cui et al.
Summary: IGF2BP2 activates ErbB2 expression by recognizing the m6A modification of YAP, thus promoting proliferation and invasion of CRC cells while inhibiting apoptosis.
Article
Biochemistry & Molecular Biology
Desheng Yang et al.
Summary: Recent evidence has shown that both N-6-methyladenosine (m(6)A) and long noncoding RNAs (lncRNAs) play crucial roles in gastric cancer (GC) tumorigenesis. This study reveals the up-regulation of lncRNA LINC00958 in GC tissue and cells, which is clinically associated with lower survival rates in GC patients. Functionally, LINC00958 was found to promote aerobic glycolysis in GC cells.
Article
Cell Biology
Xiao-Kun Wang et al.
Summary: The study showed that METTL16 was highly expressed in gastric cancer and associated with prognosis. In vitro and in vivo experiments confirmed that METTL16 promoted proliferation of GC cells and tumor growth. Furthermore, METTL16 was found to enhance proliferation of GC cells by regulating the expression of cyclin D1.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2021)
Review
Endocrinology & Metabolism
Junguo Cao et al.
Summary: IGF2BP2 plays a crucial role in the pathogenesis of both T2DM and cancer by regulating glucose metabolism, insulin sensitivity, and tumorigenesis. Studies have shown that IGF2BP2 is involved in the increased risk of certain malignancies in T2DM patients and that single-nucleotide variations of IGF2BP2 are associated with both diseases.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Oncology
Wenjie Zhou et al.
Summary: The research found that the m6A methyltransferase METTL3 promotes the proliferation and migration of gastric cancer cells by modifying YAP1 through m6A.
JOURNAL OF ONCOLOGY
(2021)
Article
Oncology
Duo Wang et al.
Summary: This study comprehensively analyzed the prognostic value of all 33 m6A RNA methylation regulators in GC, identifying fat mass and obesity-associated protein (FTO) as a key prognostic factor for overall survival (OS) of GC patients. FTO was found to promote GC metastasis by upregulating the expression of Integrin beta 1(ITGB1) via decreasing its m6A level.
FRONTIERS IN ONCOLOGY
(2021)
Review
Endocrinology & Metabolism
Ning Dai
TRENDS IN ENDOCRINOLOGY AND METABOLISM
(2020)
Article
Oncology
Jian Pu et al.
FRONTIERS IN ONCOLOGY
(2020)
Review
Biology
Abdulwahab Ali Abuderman
SAUDI JOURNAL OF BIOLOGICAL SCIENCES
(2019)
Review
Surgery
Natesh Yepuri et al.
JOURNAL OF SURGICAL RESEARCH
(2019)
Review
Cell Biology
Zhen Bi et al.
JOURNAL OF CELLULAR PHYSIOLOGY
(2019)
Article
Oncology
Christina L. Costantino et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2019)
Review
Gastroenterology & Hepatology
Yoshihiko Kawaguchi et al.
ANNALS OF GASTROENTEROLOGICAL SURGERY
(2019)
Article
Biochemistry & Molecular Biology
Jia-Jia Xuan et al.
NUCLEIC ACIDS RESEARCH
(2018)
